News & Events


Welcome to the new Synteract Blog!

Welcome to the new Synteract Blog!
01 June 2016

By Wendel Barr, CEO, Synteract

It’s an exciting month for Synteract!

First, we were recently acquired by Amulet Capital Partners, a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. In this dynamic industry, a clear imperative for Synteract is to sustain our growth and advance our capabilities to continue meeting the needs of our clients. Our recent acquisition by Amulet will help us do this, with renewed vigor around investment in tools, processes and people to help in our day to day work; a focus on hiring more impact players; and, benefiting from new energy Amulet brings as investment partners who understand the challenges and complexities of what we do to support our clients.

And today, we launch our new blog! This blog will be a forum where we address interesting topics relevant to you in our current world of drug and device discovery. Sometimes we’ll post educational tips that you can use in your everyday work life, offer an opinion on trends and innovations, maybe brag a little, or solicit questions from you on things you always wanted to know from a full-service CRO. We welcome your participation, thoughts, concerns and good stories.

In two weeks we will be exhibiting at DIA 2016, in booth #917, and our Chief Medical Advisor Dr. Stephan de la Motte will be participating on a panel that addresses the unique challenges of rare and orphan disease trials. We hope you will come and visit us there, attend Stephan’s presentation and tell us about the challenges or roadblocks you are meeting in your clinical trials. We look forward to engaging with our colleagues and clients, to better understand how we can apply our expertise to bring success to your complex trials.


Contact Synteract

Tell us how to stay in touch with you: